Hamidizadeh Ramin, Nzekwu Emeka, Halliwell Oliver
70401Cumming School of Medicine, University of Calgary, Alberta, Canada.
Can Assoc Radiol J. 2021 Nov;72(4):890-897. doi: 10.1177/0846537120981100. Epub 2020 Dec 29.
To compare long-term outcomes of transarterial (TA) and translumbar (TL) embolization of type II endoleaks (T2E) following EVAR, as well as factors that predict clinical success.
129 (mean age, 71.4y; range, 53-95) with T2E referred for embolization from August-2003 to December-2017 were retrospectively reviewed. One-hundred-eighty procedures were performed via TA (n = 139) and TL (n = 41) approaches, with 37 patients undergoing 51 reinterventions. Clinical success was defined as absence of endoleak and/or absence of aneurysm sac enlargement on follow-up imaging. Medical comorbidities, procedural data, embolic agents used, presence of successful sac embolization, and 30-day morbidity and mortality data were collected.
TL approaches had higher technical success (41/41 vs.122/139, = .014). Clinical success rates were 52% (N = 58/111) and 62% (N = 23/37) for TA and TL procedures respectively ( = .34). Looking at all procedures, sac embolization using n-butyl cyanoacrylate glue had higher clinical success compared to other embolic agents ( = .017-.037). Successful sac access was a strong predictor of success for TA procedures (46/78 vs.12/33, = .0379). 30-day complication rates were similar between TA (5.8%) and TL (4.9%) approaches. There was 1 death secondary to graft infection following TA embolization.
Overall clinical success of TA and TL embolization when considering re-interventions is high. n-butyl cyanoacrylate glue had significantly higher success than other embolic agents ( = .017-.037). Successful sac access was associated with success for TA procedures.